AbClon Inc is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
18/09/26	₩19,560.00	-2.93%	115,103
17/09/26	₩20,150.00	-0.49%	68,726
16/09/26	₩20,250.00	-2.17%	47,236
15/09/26	₩20,700.00	+2.22%	119,188
14/09/26	₩20,250.00	-1.22%	72,450

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 17/09/2026			5-day change	1st Jan Change
20,150.00 ^KRW	-0.49%		-3.36%	-52.59%

06-08	Alligator partner Henlius doses first patients in HLX22 study	FW
05-22	Alligator Bioscience comments on Henlius update for HLX22	FW

Market Cap	402B 291M 254M 240M 218M 407M 27.88B 409M 2.86B 1.11B 14.17B 1.09B 1.07B 45.36B	P/E 2024	-14.5x	P/E 2025	-43.5x
Enterprise Value	364B 264M 230M 217M 197M 369M 25.25B 371M 2.59B 1B 12.83B 991M 968M 41.08B	EV / Sales 2024	103x	EV / Sales 2025	164x
Free-Float	80.08%	Yield 2024 *	-	Yield 2025	-

06-08	Alligator partner Henlius doses first patients in HLX22 study	FW
05-22	Alligator Bioscience comments on Henlius update for HLX22	FW
04-23	Alligator partner Henlius presents preclinical data for HLX49	FW
04-23	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate	CI
04-07	Abclon wins 396 million won order	RE
03-09	AbClon wins 778 million won order	RE
03-02	Alligator Bioscience: First Patient Dosed in Phase 2/3 Study with HLX22 in China	FW
01/10/25	AbClon Inc. announced that it expects to receive KRW 35.999952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital and other investors.	CI
27/08/25	Abclon wins 309 million won order	RE
20/05/25	Abclon Wins 354 Million Won Order	RE
19/05/25	AbClon Inc To Issue 1.4 Million Common Shares	RE
19/05/25	AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.	CI
15/05/25	Abclon Wins 307 Million Won Order	RE

06-08	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
05-22	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
04-23	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
03-02	Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22	AQ
04/12/24	Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial	AQ

AbClon Inc. Stock

Stocks

A174900

KR7174900001

Pharmaceuticals

Valuation: AbClon Inc.

Chart: AbClon Inc.

Latest news: AbClon Inc.

Press Releases: AbClon Inc.

Quotes and Performance

Price Extremes

Managers and Directors: AbClon Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

1 day	-0.49%
1 week	-3.36%
Current month	-18.09%
1 month	-37.71%
3 months	-40.74%
6 months	-75.72%
Current year	-52.59%

1 week	19,500	21,800
1 month	19,500	32,200
Current year	16,250	95,800
1 year	13,360	95,800
3 years	6,810	95,800
5 years	6,810	95,800
10 years	6,810	95,800

Manager	Title	Age	Since
Jong-Seo Lee CEO	Chief Executive Officer	63	25/06/2010
Doo-Hun Kim DFI	Director of Finance/CFO	59	28/03/2024
Jong-Hoon Kim CTO	Chief Tech/Sci/R&D Officer	57	29/03/2023

Director	Title	Age	Since
Jong-Seo Lee BRD	Director/Board Member	63	-
Jung-Ho Kim BRD	Director/Board Member	62	29/03/2021
Jong-Hoon Kim BRD	Director/Board Member	57	29/03/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCLON INC.	-0.49%	-3.36%	+51.50%	+25.70%	291M
REGENERON PHARMACEUTICALS, INC.	-0.48%	-0.05%	+30.46%	-5.27%	78.83B
CSL LIMITED	-1.11%	+5.08%	-11.47%	-33.91%	60.48B
MODERNA, INC.	-2.26%	+7.46%	+507.90%	+48.56%	63.11B
SAMSUNG BIOLOGICS CO.,LTD.	-0.92%	-1.90%	-10.99%	+24.21%	46.75B
UCB	+0.58%	+2.04%	+3.10%	+153.08%	45.66B
BIOGEN INC.	+0.03%	+0.77%	+52.17%	-13.61%	32.37B
INCYTE CORPORATION	+0.41%	+5.28%	+48.70%	+114.89%	25.87B
INNOVENT BIOLOGICS, INC.	+0.47%	+3.26%	-0.77%	+142.41%	21.33B
SWEDISH ORPHAN BIOVITRUM AB	+0.52%	+2.24%	+62.63%	+103.36%	15.8B
Average	-0.32%	+2.91%	+73.32%	+55.94%	39.05B
Weighted average by Cap.	-0.60%	+3.96%	+95.58%	+40.80%

	2024	2025
Net sales	2.34B 1.69M 1.48M 1.4M 1.27M 2.37M 162M 2.38M 16.64M 6.43M 82.47M 6.37M 6.22M 264M	4.71B 3.41M 2.97M 2.81M 2.56M 4.78M 327M 4.8M 33.52M 12.96M 166M 12.82M 12.54M 532M
Net income	-16.3B -11.81M -10.28M -9.73M -8.84M -16.52M -1.13B -16.6M -116M -44.82M -575M -44.35M -43.36M -1.84B	-17.91B -12.97M -11.29M -10.69M -9.71M -18.14M -1.24B -18.23M -127M -49.23M -631M -48.71M -47.63M -2.02B
Net Debt	-4.61B -3.34M -2.91M -2.75M -2.5M -4.67M -320M -4.7M -32.79M -12.68M -163M -12.55M -12.27M -520M	-37.93B -27.46M -23.92M -22.64M -20.57M -38.43M -2.63B -38.62M -270M -104M -1.34B -103M -101M -4.28B